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Summary 
We have compared the sensitivity of donogenic interlenkin 7 (IL-7)-dependent murine B cell 
precursors with that of donogenic mature B ceUs and myeloid precursors to ct-particles from 
plutonium-238 and X radiation. All three populations are relatively sensitive, but B cell precursors 
are ultrasensitive. This differential sensitivity is also observed with corticosteroid,  etoposide, and 
cisplatin, all apoptosis-inducing drugs used in the treatment of leukemia and other cancers. Further, 
we show that x-rays and drugs induce the bulk of the B cell precursor population to undergo 
rapid apoptosis, despite the continued presence of IL-7. B cell precursors were found to express 
very low levels of BCL-2 protein compared with mature splenic B cells and their resistance to 
x-rays and corticosteroid could be enhanced by expression of a BCL-2 transgene.  These data 
have important implications for normal lymphopoiesis and for the behavior of leukemic lymphoid 
precursor  cells. 
E 
Pidemiological (1) and experimental  (2, 3) studies have 
focused attention on the possible lenkemogenic effects 
of low level, high density ionizing radiation such as c~-particles 
from various sources including phtonium-239 and radon. 
In model experiments  designed to test this possibility,  we 
attempted to calculate the mutation frequency in a marker 
gene (HPRT;  hypoxanthine-guanine phosphoribosyl trans- 
ferase) in donogenic IL-7-dependent murine B cell precursors 
exposed to high linear  energy transfer  (LET) 1 ct-partides 
emitted from plutonium-238. The surprising  outcome was 
that B cell precursors (as compared with other more primi- 
tive hemopoietic or mature B cells) were very sensitive to 
the lethal effects of c~-particle irradiation.  We also calculated 
that for most B cell precursors a single c~-partide induced 
such a low probability of survival, that the chance of producing 
mutagenic damage was very small  (Grifflths,  S.  D., S. J. 
Marsden,  E. G. Wright, M. F. Greaves, and D. T. Good- 
head,  manuscript submitted for publication.). 
A  plausible  interpretation  of  these  observations  with 
1  Abbreviations  used in thispa~r: ALL, acute lymphobhstic leukemia; BM, 
bone marrow; D37, dose of radiation (Gy) giving inhibition of colony 
growth to 37%  of unirradiated controls; LET, linear energy transfer. 
ct-particles was that B cell precursors might be ultrasensitive 
to programmed cell death or apoptosis, after DNA damage. 
Thymocytes and T cells are known to be very sensitive to 
~-irradiation and corticosteroid-induced apoptosis (4, 5) and 
IL-3-activated  myeloid progenitors from bone marrow die 
by apoptosis in the absence of growth factor (6,  7). 
The sensitivity of normal B cell precursors to apoptosis 
has not been rigorously examined but is likely to be of rele- 
vance both to the regulation of lymphopoiesis  and aspects 
of leukemic cell development, pathology, and clinical response. 
B cell (and T cell) precursors may be particularly susceptible 
to, or programmed for, apoptosis to counteract a high risk of 
acquiring mutagenic damage during lymphopoiesis (Gri~ths, 
S. D. et al., manuscript submitted for publication).  Apop- 
tosis may also act to remove dones that are either autoreac- 
tire or those that have failed to competently rearrange their 
immunoglobulin (or T cell receptor) genes (8). Finally, the 
leukemic equivalents of normal B cell precursors in children 
with common acute lymphoblastic leukemia (ALL) are in 
most cases very susceptible to therapy with apoptosis-inducing 
agents (9). This might reflect the intrinsic sensitivity of normal 
B cell precursors to apoptosis, which is also expressed in len- 
kemic cells (10, 11). 
To assess the susceptibility  of B cell precursors to apop- 
tosis following DNA damage, we have compared donogenic 
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liver with bone marrow--derived  myeloid precursors doned 
in the presence of GM-CSF and splenic B cells cloned with 
LPS for their differential sensitivity to ionizing radiation and 
apoptotic drugs. The rdatiomhip between sensitivity to apop- 
toffs and expression of the antiapoptotic BCL-2 protein has 
also been examined. 
Materials and Methods 
Source of Murine Hemopoietic Cells 
Bone Marrom  Femoral  bone marrow was obtained from groups 
of three 8-12-wk-old BALB/c mice or individual (Cbe  x  C57B1/ 
6)F1 mice. The htter strain was used to generate animals that were 
transgenic for a human BCL2-Ig transgene as previously  described 
(12). 
B Cell Precursors.  Bone marrow (BM) cells (2  x  104 cells/ml) 
were cultured for 7 d at 37~  plus 7% CO2 in McCoy's complete 
medium  containing  McCoy's  5a,  15%  FCS, pyruvate, MEM 
vitamin, 2-ME (5  x  10 -s M), amino acid supplements (GIBCO 
BRL, Gaithersburg, MD) (13) and recombinant human Ib7 (500 
U/ml; a gift from Dr. S. Gillis, Immunex, Seattle, WA and Ster- 
ling Winthrop Inc., Collegeville,  PA) (14). The cultures were fed 
at 4 d with an equal volume of  fresh medium containing l'bT. After 
culture, the nonadherent cell viability was >98% by trypan blue 
exclusion, and analysis  by fluorescent  microscopy  showed  that >90% 
of cells expressed the pre-B cell markers B220 and BP-1 (15). A 
variable minority (5-40%) of  cells expressed  cytoplasmic  IgM (C~) 
and 2-7% were cell surface Ig positive mature B cells. The latter 
were removed using anti-Ig-coated magnetic beads (Dynabeads; 
DYNAL, Oslo, Norway). Fetal  liver was obtained from 15-16 d 
BALB/c fetuses (10 pooled), and were cultured in McCoy's com- 
plete medium plus IL-7  as above for 9 d. The resulting nonadherent 
cells were >98% viable, and 98 and 87% expressed  B220 and BP-1, 
respectively; <~1% of cells were C/z positive. 
Spleen Cells.  Spleens  were obtained from groups of two 8-12- 
wk-old BALB/c  mice. Spleen fragments were teased through wire 
mesh and resuspended in  McCoy's complete medium.  In  the 
majority of experiments, spleen cells (106/ml) were cultured at 
37~  plus 7% CO2 for 3 d in McCoy's complete medium plus 
LPS (25/~g/ml, Dffco  Laboratories, Inc., Detroit,  MI) before ir- 
radiation, or the addition of drugs. After culture with LPS >90% 
of spleen cells had a lymphobhstoid morphology, expressed cyto- 
plasmic and/or cell surface Ig. Cell cycle analysis  by flow cytom- 
etry (16) showed that "~30% of bhsts had entered S/G2M. 
Cloning of B  Cell Precursors, LPS Reactive Mature B  Cell 
Blasts, and Myeloid Precursor Cells 
B Cell Precursors.  BM-derived  B cell precursors were cloned in 
agar as described by Lee et al. (13). Briefly, 2  x  10  s BM cells 
without culture, or B cell precursors grown in IL-7 for 7 d were 
cloned  in three replicate  35-ram dishes  containing 1.0 ml of  McCoy's 
complete medium plus human Ib7 (500 U/nil) and 0.3%  agar. 
B cell precursors colonies were scored after 6 d of culture at 37~ 
plus 7% CO2. Colony data (mean _+  1 SEM) after exposure to 
a-particles, x-rays, dexamethasone,  etoposide, and cisphtin are from 
3-7 replicate experiments. 
Spleen B Cells.  5  x  104 spleen cells with or without LPS 
preactivation were cloned in replicate dishes containing 1.0 ml of 
McCoy's complete medium plus LPS (25/~g/ml) and 0.3% agar. 
B cell colonies were scored after 4 or 6 d; with or without LPS 
preactivation, respectively.  Colony data (mean +  1 SEAM) after ex- 
posure to cx-particles, x-rays,  dexamethasone,  etoposide, and cisphfin 
are from four replicate experiments. 
Myeioid Precursors  (CFU-GM).  2  x  10  s BM cells were cloned 
in replicate 35-mm dishes containing 1.0 ml of ILPMI 1640, 10% 
FCS, L-glutamine,  peuidllin, streptomycin  0.3% agar (Difi:o  Labora- 
tories Inc.), and murine GM-CSF (20 U/nil; British Biotech, Ox- 
ford, UK). CFU-GM colonies were scored after 6 d of culture at 
37~  plus 7% CO2. Colony data (mean +  1 SEM) after exposure 
to either x-rays  or dexamethasone,  etoposide and cisplatin are from 
two or four experiments, respectively. 
The cloning efficiency  of CFU-GM, B cell precursors and LPS- 
reactive B ceU colonies in spleen were linear with respect to the 
numbers of  cells phted: 0.1 + 0.01, 0.8 + 0.06, and 0.5 + 0.06% 
for CFU-GM, B cell  precursors, and LPS reactive  B cells, respectively. 
Addition of Dexamethasong Etoposide, and Cisplatin 
CFU-GM,  B cell precursors (cultured in the presence of IL-7 
for 7 d) and LPS preactivated  spleen  cells  were cloned in 0.3% agar 
as above  in the presence and absence of  deaamethasone  (0.001 nM-10 
/~M; Sigma Chemical  Co.,  St.  Louis, MO),  etoposide (1.25 
ng/ml-l.25/~g/ml;  Bristol Meye~ Pharmaceuticals,  Evansville,  IN) 
and cisplatin (20 ng/ml-l.25 ~g/ml). 
Irradiation with x-rays and c~.particles 
Low LET x-rays.  Bone marrow (immediately after collection), 
fetal liver or BM cells grown in IL-7 for 9 and 7 d, respectively, 
and spleen cells (+ LPS preactivation for 3 d) were exposed at ,,o2 
x  104 cells/ml in McCoy's complete medium plus II.-7 or LPS to 
x-rays (0-5 Gy) where the source (Pantak Ltd., Reading, UK) was 
set to 240 kV and 10 mA. The dose rate was 0.95-1.0 Gy/min. 
In some experiments, the dose rate was reduced to 0.05 Gy/min. 
High LET or-particles.  Bone marrow cells, 7 day Ib7-respon- 
sire B cell precursors, or spleen cells (+  LPS preactivation) were 
exposed to cx-particles (LET 121 kilo-electron volts/~m) from a 
plutonium-238 source, as described  elsewhere (17). After exposure, 
the cells  were plated directly in CFU-GM, B cell precursor, or LPS 
colony assays. 
An,,lm of Apoptosi   DNA F g,,,  tion 
Flow Cytometry.  B cell precursors (cultured in ID7 for 7 d) ei- 
ther exposed to x-rays  (0.95-1.0 Gy/min), or dexamethasone~  etopo- 
side, and cisplatin  were ctiltured in McCoy's complete medium plus 
Ib7 for up to 24 h at 37~  plus 7% COz. In some experiments, 
cyclohexamide (Sigma Chemical Co.;  0.1  ~g/ml) was present 
throughout the culture period. After culture, the cells were fixed 
in 500/zl of 70% ethanol and resuspended  in 1.0 ml of phosphate- 
buffered  saline  containing propidium iodide (20 ~g/ml) and RNAse 
(100 ~g/ml) (both from Sigma Chemical Co.). The cell suspension 
was incubated at 37~  for 30 rain and cell cycle  analysis  was per- 
formed using a FACScan  |  (Becton Dickinson & Co., Mountain 
View, CA), where the apoptotic cell fraction was detected in the 
red fluorescent sub-G1 peak (16). The data is expressed as a ratio 
between the apoptotic sub-G1 had Go/G1 peaks. 
Gel Electrophoresis.  10  ~ B cell precursors, either exposed to x- 
rays or cultured in the presence of dexamethasone, etoposide" and 
cisplatin as above, were lysed in Ikis (10 mM) EDTA (1.0 mM) 
proteinase-K  buffer containing proteinase-K  (100 ~g/ral). After in- 
cubation at 37~  for 8 h, DNA was phenol extracted as essentially 
described by (18). DNA fragmentation was resolved  by ethidium 
bromide agarose (1.5%) gel electrophoresis. 
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Endogenous BCL-2 protein was detected in paraformaldebyde/ 
methanol-fixed cytocentrifuge smears by indirect immunofluores- 
cence using a polyclonal rabbit antibody raised against a BCL-2 
synthetic peptide based on murine BCL-2 sequence information 
(19; Krajewsky, S., andJ. C. Reed, manuscript submitted for pub- 
lication). Controls consisted of  either normal rabbit Ig or blocking 
with the relevant synthetic peptide. Expression  of the human BCb2 
protein derived from the BCL2-Ig transgene was similarly  detected 
using a monoclonal anti-human BCL-2 reagent as previously de- 
scribed (20). In some experiments, the expression of the BCL,2-Ig 
transgene in either B cell or myeloid progenitor cells was measured 
by double immunolluorescence  staining using BCL-2 antibody with 
BP-1 or MAC-1 monoclonal antibodies as a marker for B cell 
precursors and myeloid progenitor cells respectively. Binding of 
BCL-2, BP-1, or MAC-1 antibodies was assessed using FITC- or 
PE-labeled second layer  antibodies, followed  by confocal  microscopy. 
Results 
The sensitivities of clonable myeloid progenitor,  B cell 
precursor and mature B cells were assayed following in vitro 
exposure to either low LET x-rays, or high LET c~-partides 
as sources of ionizing radiation. The x-ray and ol-particle dose 
giving 37%  survival (037) of the clonable fraction for the 
different cell types is presented in Table 1 and Fig. 1 A. When 
these data are compared, both  mature B  cells  (with  and 
without LPS preactivation) from spleen and myeloid progen- 
itor cells derived from BM had similar sensitivities to the 
lethal effects of x-rays. In contrast, B cell precursors present 
in BM or fetal liver (with and without IL-7 preculture) were 
ultrasensitive  as  reflected in  very low  D37  doses.  B  cell 
precursors were also very sensitive to x-ray damage when a 
reduced x-ray dose rate of 0.05  Gy min -1 was employed; 
D37, 0.22  _  0.02 Gy. Similarly, the 037 for B cell precursors 
exposed to high density ionizing c~-partides were smaller than 
those obtained for mature B ceils in spleen. 
It seemed likely that the inhibition of donogenicity by 
x-rays or c~-particles was due to apoptosis.  We therefore com- 
pared the same three donogenic cell populations for senti- 
tivity to apoptosis-inducing drugs used in the treatment of 
leukemias and other cancers; corticosteroid (dexamethasone), 
an epipodophyllotoxin (etoposide/VP16), and cisplatin. The 
drug dose response curves (Fig. 1, B-D) and the extrapolated 
drug doses resulting in either 50% (inhibitory dose [ID] 50) 
or 90% (ID 90) inhibition of  colony growth (Table 2) demon- 
strated that B cell precursors were strikingly more sensitive 
than mature B calls or myeloid progenitors to dexametha- 
sone and etoposide. B cell precursors were also more sensi- 
tive than mature B cells and myeloid progenitors to cisplatin 
but the difference was much less marked than with x-rays 
and etoposide (Fig.  1 D, Table 2). It may be significant that, 
in contrast to x-rays and etoposide that induce double-stranded 
DNA breaks, cisplatin is a DNA cross-linker. 
Apoptosis can be assayed by measuring DNA fragmenta- 
tion by flow cytometry or by agarose gel dectrophoresis. Cy- 
dohexamide also inhibits apoptosis by inhibiting protein syn- 
thesis (16). To further explore the involvement of apoptosis 
in the sensitivity of B cell precursors ceils to ionizing radia- 
tion and drugs, we next documented the response of the total 
IL-7 expanded B cell precursor population to x-rays,  dexa- 
methasone, etoposide, and cisplatin.  B cell precursors exposed 
to x-rays or drugs underwent apoptosis as indicated by flow 
cytometry; the ratio of sub-G1 to GO/G1 DNA cell content, 
calculated from the areas in histogram regions I and 2, respec- 
tively, (shown next to the DNA profiles in Fig. 2), increased 
rapidly between 2 and 24 h of culture. DNA fragmentation 
in B cell precursors was also detected by agarose gel electropho- 
resis. The nucleosomal DNA ladder characteristic for apop- 
totic cells was observed after exposure to x-rays,  or culture 
with either dexamethasone, etoposide or cisplatin (Fig.  3, 
lanes 2-5)  when compared with controls (Fig.  3,  lane 1). 
B cell precursor apoptosis induced by x-rays could also be 
Table  1.  Sensitivity of Myeloid Progenitor, B Cell Precursor  (pre-B), and Mature-B Clonogenic Cells to the Lethal Effects of X-rays and c~-Particles 
Colony-forming  ~-partides*  x-rays* 
Lineage  cells  (D37:Gy)  (D37:Gy) 
Myeloid 
Lymphoid 
CFU-GM  ND  1.4  _+  0.1 
BM,  pre-Bt  0.39  _+  0.03  0.31  _+  0.02 
BM,  pre-B  +  IL-7S  0.22  +  0.03  0.24  +  0.01 
FL,  pre-B  +  IL-7n  0.18  _+ 0.04  0.15  _+ 0.005 
Splenic mature B  1.16  _+ 0.04  1.2  _+ 0.1 
Splenic mature B  +  LPSI  1.1 _+ 0.2  1.0 +  0.1 
* Dose in Gray (Gy) for 37% survival (D37) was calculated from a least square regression fit of data from replicate experiments to the linear equation 
for logarithm of donable fraction vs. dose. 
BM, irradiated immediately  after collection. 
s BM, cultured with IL-7 for 7 d before irradiation. 
n Fetal liver from  a pool of eight mice; cultured with IL-7 for 9 d before irradiation. 
￿82  With LPS preactivation  for 3 d. 
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Figure  1.  Survival  of clonable 
CFU-GM, i-i;  mature B cells, 
I-q-D;  and  B  precursors,  0-0; 
after  exposure  to:  (/1)  x-rays; or 
in the presence of: (B) deaarnetha- 
sone; (C) etoposide; and (D) cispla- 
tin. Data represents the mean +  1 
SEM.  from replicate  experiments 
(Materials  and  Methods),  where 
bone marrow or spleen was obtained 
from pools of two or three  mice. 
B  cell precursors  and  spleen cells 
were precultured in IL-7 or LPS for 
7 or 3 d, respectively, before assay. 
Table  2.  Sensitivity of Clonogenic Myeloid Precursor, B Cell Precursor  (Pre-B) and Mature B Cells to Dexamethasone, Etoposide, and Cisplatin 
ID 
Colony-  (%  control 
Lineage  forming ceils  inhibition)  Dexamethasone*  Etoposide*  Cisplatin* 
Myeloid:  CFU-GM 
Lymphoid:  BM,  pre-B  +  IL-7* 
Splenic mature  B  +  LPSS 
nM  ng/ml  ng/ml 
50  Resistant  108  •  8  230  •  45 
90  Resistant  230  •  30  500  •  37 
50  0.4  _+  0.14  3.2  •  1.3  50  •  9 
90  1.1  •  0.2  8.5  •  5.3  160  •  29 
50  29  _+  21  94  •  10  88  •  10 
90  4,730  •  2,100  160  •  19  280  •  52 
* Data represents  the mean  _  1 SEM from replicate experiments 
or three  mice. 
* BM, cultured with Ib7 for 7 d before assay. 
$ With LPS preactivation  for 3 d. 
(Materials  and Methods),  where BM or spleen was  obtained  from pools  of two 
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Figure 2.  TLme  course for B precursor cell apoptosis as detected by flow cytometry after exposme to x-rays (3.0 Gy) or in the presence off dexametha- 
sone (0.1/~M), etoposide (0.16 gg/ml), and cisplatin (10/~g/ml). Regions 1-3 represent cells with sub~l, G0/G1, or S/G2M DNA content, resla~ctively. 
Data are expressed as the ratio between the sub-G1 and G0/G1 peaks. 
largdy, but not completely, inhibited by cyclohtmamide, as 
measured by flow cytometry, where rescue of  cells expressing 
G0/G1 DNA content was observed (Fig. 4). The total,  al- 
beit heterogeneous, B cell precursor population was more sen- 
Figure 3.  DNA fragmentation 
as detected by PAGE dcctropho- 
resis for B cell precunors exposed 
to  x-rays and apoptotic drugs: 
Gy) 4 h culture; (lanes 3-5) dcxa- 
methasone  (0.1 /an),  etoposide 
(0.16/~g/ml),  and cisphtin (10 
gg/ml), resprctivdy. 24 h colmr~ 
sitive to x-ray-induced apoptosis at 8 h of culture than the 
total LPS-activated splenic B cell population where sub G1 
to G0/G1 DNA peak ratios of 7.72 vs. 0.77 respectively  were 
observed.  Withdrawal  of IL-7  from proliferating  B  cell 
precursors also prompted a rapid onset of apoptosis (not 
shown) as previously reported (21). Thus in common with 
IL-3-dependent hemopoietic progenitors,  IL-7 can exert an 
antiapoptotic function in B cell precursors but is, in the con- 
centration range used, incapable of  preventing  x-ray or drug- 
induced inhibition of colony formation by donogenic  B cell 
precursors (despite  providing a proliferative  stimulus), or apop- 
toffs of the total population. 
The vulnerability of B cell precursors to apoptosis could 
be due to the pattern of expression  of gene products including 
BCL-2 (22), and related apoptosis-regulating genes (23-25). 
We found that levels of BCL-2 protein in B cell precursor 
populations as assessed  by antibody staining and confocal mi- 
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~~.  1.25  Figure 4.  DNA  analysis from  B  cell 
precursors  ~posed m x-rays  (3.0 Gy) and cul- 
ture:! in the presence  or absence  of  cyclohexi- 
mide (0.1/~g/ml) for 8 h. Regions 1-3 repre- 
sent cells with sub-G1, G0/G1, or S/G2M 
DNA content,  respectively.  Data  are expressed 
as the ratio  between  sub-G1 and G0/G1 peaks. 
croscopy were very low as compared with lymphocytes in 
spleen (Fig. 5, C and A, respectivdy), as previously suggested 
when stable  mRNA levels were used as a marker (26, 27). 
This parallds the very low levels of  BCL-2 protein in thymo- 
cytes with  T  cell precursor  phenotypes  (CD4 +,  CDS+; 
references 28,  29). 
A BCL-2  transgene has been shown to protect thymocytes 
from steroid and radiation-induced apoptosis (30-32). Simi- 
larly, a retroviraily packaged BCL-2 gene was shown to pro- 
tect IL-7-dependent B cell precursor cell lines from apop- 
tosis  after removal of IL-7 (21).  We assessed the ability of 
a human BCL-2-Ig transgene (12) to protect murine B cell 
precursors.  The human transgene was highly expressed in 
•90%  of BP-l-positive BM B ceil precursors from trans- 
genic  mice  as  assessed  by  two-color  immunofluorescent 
staining.  Furthermore, BCL.2-Ig expression was restricted 
to the lymphoid lineage, since >99% immature MAC-1 posi- 
tive myeloid cells present in the BM from the same animals 
failed to stain for human BCL-2 (data not shown). The IL- 
7-dependent cloning efficiency was similar in transgenic (0.14 
+  0.03%)  and control age and strain (Chex C57BR/6)Fi 
matched mice (0.17  +  0.06%).  As anticipated, the total B 
cell precursor population expressing the BCL-2-Ig  transgene 
had markedly increased resistance to x-ray (after 8 h of cul- 
ture) and deaamethasone (after 24 h of  culture) induced apop- 
tosis,  where the ratio of sub G1 and GO/G1 DNA contents 
were small and close to control values  (Fig.  6,  legend). A 
modest increase in the survival of clonable B cell precursors 
to the lethal effect of x-rays was observed in cells obtained 
from four of the six BCL-2-Ig mice, as compared with age 
and strain matched controls (Fig.  7). A distinct shoulder in 
the x-ray survival curves from the BCL-2-Ig mice was also 
present, indicating that the inhibition or delay of apoptosis 
had allowed some DNA repair to occur. Why this effect was 
absent in two of the mice is unknown, but could reflect vari- 
able levels of  BCL-2-Ig expression in clonable B cell precursors 
which may be more primitive than the majority of the B 
cell precursor population. Alternatively, the BCL-2 protein 
may fail to substantially inhibit apoptosis in the long time 
frame (6 d) of the donogenic assay. 
Fil~,e s.  Splem  celh and B 
cell precursors  stoned for BCb.2 
protein, (A)  spleen cells plus 
BCb2 antibody, (B) spleen 
plus conu'ol  rabbit serum,  (C)  B 
cell Fecunon plus BCb2 anti- 
body. (D) B cell precurson  plus 
rabbit sen.un. 
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Figure 6.  DNA analysis from B cell precursors (with and without ex- 
pression of the BCL.2 transgene) after exposure to x-rays (3.0 Gy, 8 h cul- 
ture), or in the presence of dexamethasone (0.1/an, 24 h culture). R~ons 
1-3 represent cells with sub-G1, G0/G1, and S/G2M DNA content. Data 
are expressed as the ratio between the sub-G1 and G0/G1 peaks. Controls 
(B cell precursors not exposed to x-rays or dexamethasone) gave mean + 
1 SEM ratios of 0.06  + 0.01 and 0.14 +  0.03 in the presence and absence 
of the BCL-2 transgene. 
A minor decrease in sensitivity of donogenic IL-7-depen- 
dent B cell precursors to dexamethasone was also observed 
with ceil populations expressing the BCL-2 transgene (not 
shown). The lack of substantial rescue of BCL-2-expressing 
cells in the donogenic (i.e., proliferation-dependent) assay 
with dexamethasone, could be due to BCL-2-delaying apop- 
tosis in a 6-d assay. Alternatively, we cannot exclude that 
BCL-2 did provide effective protection from apoptosis but 
did not prevent inhibition of B cell precursor proliferation by 
steroid (33). 
Discussion 
The significance of these results is twofold. First, with re- 
spect to the developmental biology orB lymphoid cells, they 
suggest that precursors at the stage of IL-7 dependence (13, 
34, 35) are extraordinarily sensitive to both ionizing radia- 
tion and to apoptosis-inducing drugs.  It seems likely that 
this feature is linked to the pronounced developmental loss 
of dividing B ceil precursors in BM as deduced by kinetic 
studies (36). Sensitivity of dividing B cell precursors to both 
experimentally induced and developmentally regulated apop- 
tosis might be dependent upon the level of expression and 
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Figure 7.  Survival ofdonogenic IL-7-dependent B cell precursors from 
individual BCL-2 transgenic mice after exposure to x rays, l-I,  r-l-D, 
e-e,  x-x,  A-A, A-A, or pooled data (mean  _+  1 SEM) from five 
control mice lacking the Bd-2-Ig transgene, O-O. B cell precursors from 
all transgenic mice expressed the Bd-2-Ig transgene by immunofluores- 
cence staining and confocal microscopy. 
activity of a number of gene products that are known to be 
involved in the regulation of apoptosis including BCL-2 (22), 
the BCL-2-related genes BAX (23) and BCL-x (24), p53 (37), 
c-MYC  (38)  protein  tyrosine kinases  (39),  as well  as en- 
donuclease (40) and DNA repair enzymes (41). Our data in- 
dicates that ultrasensitivity of IL-7-dependent B cell precxu~rs 
in apoptosis is associated with very low levels of BCL-2 pro- 
tein expression. Others have recently reported low levels of 
BCL-2  mRNA  in murine B  cell precursors  (26,  27)  but 
mRNA and protein levels for BCL-2 may not always be con- 
cordant (42). However, as shown here with single cell staining, 
the  great  majority  of BP-1 +  IL-7-dependent  B  ceil pre- 
cursors have little or no detectable BCL-2 protein. 
Although in principle a similar apoptotic pathway is func- 
tional in most myeloid precursors and mature (activated) B 
cells (7, 8), they appear to have a considerably higher threshold 
for apoptosis induction in the presence of a proliferative signal. 
Immature T cells or cortical thymocytes as a population are 
very sensitive to apoptosis-inducing ~/-radi'ation  and steroid 
(4,  5, 43) and it may be that donogenic T  cell precursors 
are as sensitive as the B cell precursors assayed here, although 
this has not yet been reported. In this context, the marked 
sensitivity of the apoptotic response in lymphoid precursors 
may be linked to a stringent requirement for donal dimina- 
tion of cells with nonfimctional or self-reactive antigen receptor 
rearrangements; successful response to a differentiation signal 
would then be required to override the default cell death re- 
sponse. A  similar selection appears to operate for a subset 
of mature B cells in germinal centers (44). Lymphocyte pro- genitors are unusual but not unique in their ultrasensitivity 
to ionizing radiation since primordial  oocytes and a subset 
of spermatogonal cells are equally if not more sensitive (45). 
Lymphocyte precursors,  in common with germ cells,  have 
the dual features of recombinatorial genetic activity with ex- 
treme longevity of donal offspring;  vulnerability to apop- 
tosis may in this context be required by both types of cells 
as a sensitive and e~dent mechanism for diminating DNA 
damaged ceUs. It is interesting in this respect that B and T 
lymphoid cell progenitors at the earliest developmental stage 
before active immunoglobulin or T  cell receptor gene rear- 
rangement  appear to express high levels of BCL-2 (27, 29, 
46); it can be anticipated that these cells will be more resis- 
tant to apoptosis induced by ionizing radiation  and drugs. 
Second, we initially selected B cell precursors for these ex- 
periments as the normal  murine counterparts  of the likely 
"target" cell population for the major subtype of childhood 
cancer, common, B cell precursor ALL (10, 47). This leukemia 
was the first disseminated and otherwise lethal cancer to be 
curable by chemotherapy and X ~r-~l_i~tion  (9), a success repeated 
with very few other cancers; Wilm s turnout, Hodgkin's dis- 
ease, and testicular teratoma being significant  e~eptions. The 
biological basis for what appears to be an intrinsic curability 
of the majority of childhood ALL and a ~  other cancers 
has been an enigma.  It is now recognized that many drugs 
used in the therapy of cancer and leukemia operate via the 
induction of apoptosis (48, 49) and that clonogenic leukemic 
cells are likely to vary in their vulnerability to induced apop- 
tosis (11, 50, 51). Clonogenic leukemic B cell precursors in 
ALL with developmentally programmed ultrasensitivity to 
apoptosis and in differentiation arrest, would be expected to 
be very sensitive to drug treatment;  the essential caveat  is 
that leukemogenic mutations should not, in most cases, over- 
ride the apoptotic response (11). 
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